Get the Stockscreener App
117.07
4.70%
-5.78
After Hours:
117.07
Repligen Corp stock is traded at $117.07, with a volume of 1.15M.
It is down -4.70% in the last 24 hours and down -5.88% over the past month.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
See More
Previous Close:
$122.85
Open:
$121.6
24h Volume:
1.15M
Relative Volume:
1.38
Market Cap:
$6.58B
Revenue:
$633.51M
Net Income/Loss:
$-8.10M
P/E Ratio:
-377.65
EPS:
-0.31
Net Cash Flow:
$131.26M
1W Performance:
-3.94%
1M Performance:
-5.88%
6M Performance:
-29.57%
1Y Performance:
-30.04%
1-Day Range:
$116.76
$122.72
1-Week Range:
$116.76
$132.24
52-Week Range:
$102.97
$182.52
Repligen Corp Stock (RGEN) Company Profile
Name
Repligen Corp
Sector
Industry
Phone
(781) 449-9560
Address
41 SEYON STREET, WALTHAM, MA
Compare RGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
117.07 | 6.90B | 633.51M | -8.10M | 131.26M | -0.31 |
|
ISRG
Intuitive Surgical Inc
|
481.09 | 179.42B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
178.25 | 52.03B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.55 | 44.11B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
271.94 | 40.68B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
239.26 | 17.92B | 2.90B | 467.20M | 306.90M | 6.37 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-29-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | Evercore ISI | In-line |
| Feb-10-25 | Initiated | TD Cowen | Buy |
| Dec-17-24 | Initiated | Canaccord Genuity | Hold |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-26-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jun-18-24 | Initiated | Guggenheim | Neutral |
| Dec-04-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-20-23 | Initiated | Wells Fargo | Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Mar-28-23 | Initiated | The Benchmark Company | Buy |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-22 | Initiated | UBS | Buy |
| Oct-14-21 | Initiated | Exane BNP Paribas | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| May-07-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-23-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Nov-01-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Oct-15-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-19 | Reiterated | First Analysis Sec | Outperform |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jul-22-19 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-17-18 | Upgrade | CL King | Neutral → Buy |
| Nov-12-18 | Downgrade | CL King | Buy → Neutral |
| Sep-26-18 | Initiated | H.C. Wainwright | Neutral |
| Dec-08-17 | Initiated | Citigroup | Buy |
| Dec-05-17 | Initiated | JP Morgan | Overweight |
| Nov-13-17 | Initiated | CL King | Buy |
| Oct-02-17 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Jul-21-17 | Initiated | William Blair | Outperform |
| Feb-13-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Repligen Corp Stock (RGEN) Latest News
Why is Repligen Corporation stock attracting strong analyst attentionBeginner Investor Tips With Low Risk - jammulinksnews.com
Repligen Stock Outlook: Risk Skewed To The Downside Through 2026 - Benzinga
Repligen (RGEN) Partners with Novasign to Enhance Filtration Systems - GuruFocus
Repligen Corporation (NASDAQ:RGEN) Q2 2025 Earnings Call Transcript - Insider Monkey
Repligen partners with Novasign to enhance bioprocessing systems - Investing.com
Repligen partners with Novasign to enhance bioprocessing systems By Investing.com - Investing.com Canada
Repligen Accelerates Biotech Revolution: AI Partnership Promises 70% Faster Drug Development - Stock Titan
Repligen Corporation (NASDAQ:RGEN) Shares Sold by Norden Group LLC - Defense World
Repligen Corporation (NASDAQ:RGEN) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Repligen Corporation stock outlook for YEARFast Movement Forecast for Trading Success - Newser
Can trapped investors hope for a rebound in Repligen CorporationIntraday Strategy with Real Time Monitoring - Newser
What candlestick patterns are forming on Repligen CorporationFree Real Time Stock Movement Analysis - Newser
Repligen stock rating reiterated at Overweight by KeyBanc on bioprocessing growth - Investing.com Canada
Sector ETF performance correlation with Repligen CorporationAI Volatility Forecast and Risk Monitor - Newser
Evaluating Repligen Corporation with trendline analysisFree Conservative Long Term Growth Plans - Newser
Can Repligen Corporation recover in the next quarterDaily Pattern Analysis with Return Forecast - Newser
Thornburg Investment Management Inc. Sells 1,646 Shares of Repligen Corporation (NASDAQ:RGEN) - Defense World
North Star Asset Management Inc. Sells 334 Shares of Repligen Corporation (NASDAQ:RGEN) - Defense World
Repligen Corp (RGEN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges - Investing.com Canada
Why Repligen Corporation stock attracts strong analyst attentionShort Term Buy Zone Stock Alerts Signal Entry - metal.it
Repligen Corporation Forms Bullish Flag — Upside AheadTriple Digit Return Stock Predictions Released - metal.it
Earnings call transcript: Repligen Q2 2025 revenue beats forecast, stock surges - Investing.com
Repligen shares surge as bioprocessing firm beats revenue expectations - Investing.com
Repligen: Q2 Earnings Snapshot - San Antonio Express-News
Repligen Corp. Q2 Earnings: Mixed Results with Revenue Surpassing ExpectationsNews and Statistics - IndexBox
Repligen’s (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance Is Optimistic - Barchart.com
Repligen earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Repligen Corporation Reports Q2 2025 Revenue of $182 Million, Achieving 15% Year-Over-Year Growth and Raises Full-Year Guidance - Quiver Quantitative
Repligen Corporation Reports Second Quarter 2025 Financial Results - TradingView
Biotech GC Says She Was Ousted Amid 'Systemic' Bias - Law360
Repligen Corp (RGEN) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Repligen Corp (RGEN) Q2 2025 Earnings Report Preview: What To Ex - GuruFocus
Will breakout in Repligen Corporation lead to full recoveryFree Fast Exit and Entry Strategy Guide - Newser
What momentum shifts mean for Repligen Corporation Free Weekly Potential Breakout Stock List - Newser
Repligen (RGEN) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo.co
Is Repligen Corporation stock overvalued or undervaluedSky-high return potential - jammulinksnews.com
Repligen Corporation Stock Support and Resistance Levels You Should KnowVerified Chart Patterns - Newser
How Repligen Corporation stock performs during market volatilitySmart Money Signals - Newser
Cerity Partners LLC Sells 1,461 Shares of Repligen Corporation (NASDAQ:RGEN) - Defense World
Repligen (RGEN) to Release Earnings on Tuesday - Defense World
What drives Repligen Corporation stock priceFree Predictions - Autocar Professional
What institutions are buying Repligen Corporation stock nowExceptional profit margins - jammulinksnews.com
Repligen Corporation (NASDAQ:RGEN) Shares Purchased by Signaturefd LLC - Defense World
Repligen’s 39% decline validates InvestingPro’s January 2024 bearish call By Investing.com - Investing.com
What analysts say about Repligen Corporation stockBreakthrough profit margins - jammulinksnews.com
Repligen (RGEN) Receives Overweight Rating with $160 Price Targe - GuruFocus
Here's Why Repligen (RGEN) is a Strong Growth Stock - Yahoo Finance
Repligen FY2025 EPS Forecast Increased by Leerink Partnrs - Defense World
Is Repligen Corporation a good long term investmentRapid profit acceleration - PrintWeekIndia
What is Leerink Partnrs’ Forecast for Repligen Q1 Earnings? - Defense World
Envestnet Asset Management Inc. Reduces Position in Repligen Corporation (NASDAQ:RGEN) - Defense World
Repligen Corp Stock (RGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
22.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):